Neuralink Wins FDA Breakthrough Status, But Blindness Cure Claims Are Premature
Neuralink receives FDA breakthrough device clearance for its Blindsight implant, though experts caution this designation does not equate to a proven cure for blindness. The technology still faces significant hardware limitations despite Elon Musk's ambitious public statements.
Neuralink receives "breakthrough device" clearance from the FDA for its Blindsight system, a designation that simply expedites the premarket review process rather than confirming a medical cure. This voluntary program grants the company priority review and increased interaction with FDA experts, a status that 145 other medical devices also earn in 2023 alone.
The Blindsight implant builds on decades of experimental technology that embeds a microelectrode array in the visual cortex to stimulate neurons based on camera input. Neuralink's main advancement is an increase in electrode density, but the fundamental drawbacks of the approach remain, as the resulting visual phenomena historically resemble only a few random, winking stars rather than actual sight.
Despite Elon Musk's claims that the device will allow people who are blind from birth to see, experts point out that these assertions are extremely premature. Even for individuals who recently lose their sight, adapting to this type of cortical stimulation is a difficult and disorienting process, and it does not simply plug in to grant immediate vision like Atari graphics.